Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519
Aktis Oncology has initiated a Phase 1b clinical trial for its miniprotein radioconjugate, AKY-2519, which targets B7-H3.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Aktis Oncology starts second Phase 1b trial for AKY-2519
Aktis Oncology said it initiated a second Phase 1b clinical trial for AKY-2519, a miniprotein radioconjugate targeting B7-H3.